Search

Your search keyword '"Philis-Tsimikas, Athena"' showing total 478 results

Search Constraints

Start Over You searched for: Author "Philis-Tsimikas, Athena" Remove constraint Author: "Philis-Tsimikas, Athena"
478 results on '"Philis-Tsimikas, Athena"'

Search Results

106. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes

110. Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE.

111. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.

112. Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study

113. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

114. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.

115. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.

116. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials

121. Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

123. Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial

125. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges

127. Within-day Variability Based on 9-point Profiles Associates with Overall and Nocturnal Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D)

128. Day-to-day Variability of Fasting Self-Measured Blood Glucose (SMBG) Associates with Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D)

130. Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes

132. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

133. L’insuline Faster Aspart vs insuline asparte en prandiale en double aveugle améliore le contrôle glycémique chez le DT1 : étude onset ® 1

135. Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

138. Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial

141. Nurse Managed Program for Diabetes in Low Income Latino Populations (Project Dulce) Improves Care and Alters Culture Bound Beliefs

142. Nurse Management Improves Diabetes Care in a Managed Care Setting

145. Introduction

146. Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

150. Cost-Effectiveness of Diabetes Case Management for Low-Income Populations

Catalog

Books, media, physical & digital resources